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doi:10.1016/j.ahj.2009.09.019Coronary heart disease is a major cause of morbidity
and mortality worldwide. Although percutaneous coro-
nary intervention (PCI) and coronary artery bypass graft
(CABG) are 2 fundamental treatment modalities for
coronary heart disease, patients remain at risk for adverse
cardiovascular events even after successful revasculariza-
tion. The growing number of acute coronary syndrome
(ACS) patients with prior coronary revascularization
demands the implementation of robust evidence-based
management strategies to optimize clinical outcomes.
Yet, patients with prior coronary revascularization,
especially those with prior CABG, have often been
underrepresented in or excluded from clinical trials.1-3
Current American College of Cardiology/American
Heart Association guidelines4 support an early invasive
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Volume 159, Number 1strategy in non-ST elevation ACS (NSTE-ACS) patients
without serious comorbidity who had PCI in the past 6
months or prior CABG. However, there are limited data
on the management pattern of these patients in the “real
world.” Accordingly, we used data from the Canadian
Global Registry of Acute Coronary Events (GRACE/
expanded-GRACE), Canadian ACS Registries I and II to
examine the medical treatment and use of invasive
cardiac procedures in relation to prior revascularization
among NSTE-ACS patients.5-10
Methods
Study design
Details of the Canadian Acute Coronary Syndrome Registries
(ACS I and ACS II)9,10 and the Global Registry of Acute Coronary
Events (GRACE/expanded-GRACE)5-8 have been previously
described. Briefly, the Canadian ACS Registries were prospec-
tive, multicenter, observational studies focusing on the epide-
miology, management practices, and outcomes of ACS.9 In ACS
Registry I, 51 Canadian hospitals provided data during the
period between September 1999 and June 2001. Thirty-six
Canadian centers participated in the ACS Registry II and
recruited patient from October 2002 to December 2003. In
these registries, patients were eligible9 if they were (1) aged
≥ 18 years on presentation, (2) admitted to hospital with
symptoms qualifying for ACS within 24 hours of onset, and (3)
the qualifying ACS was not precipitated by a major comorbidity,
such as gastrointestinal bleeding or trauma. To minimize
selection bias, no other exclusion criteria were applied.
GRACE was a prospective multinational registry of patients
with the full spectrum of ACS.5,6,8 Expanded-GRACE was an
expansion of GRACE that was started in 2003 to provide
opportunities for additional hospitals to enroll their ACS
patients.7 In total, 53 Canadian hospitals participated in the
GRACE/expanded-GRACE from 1999 to 2007. Eligible patients
were (1) ≥ 18 years of age and alive on presentation to hospital;
(2) admitted to the hospital with symptoms consistent with
acute cardiac ischemia within 24 hours of onset with at least one
of the following: electrocardiographic changes indicating ACS,
increased biochemical markers of myocardial necrosis, or
documented evidence of coronary artery disease; and (3)
symptoms were not precipitated or accompanied by a serious
concurrent illness. To reduce any selection bias and to enhance
the generalizability of the findings, GRACE and expanded-
GRACE recruited the first 10 to 20 patients per month if there
were N120 eligible patients admitted to these hospitals in 1 year.
In all 3 registries, patients were diagnosed with ST-segment
elevation myocardial infarction (MI) if they had presumably new
1-mm ST-segment elevation on 2 contiguous leads or new left
bundle branch block on their electrocardiogram and abnormal
cardiac biomarker. Because our focus is the use of invasive
strategy in the management of NSTE-ACS, we excluded patients
with ST elevation MI and those with a final non-ACS diagnosis in
this study. Of the Canadian hospitals participating in ACS
Registries I and II and GRACE/expanded-GRACE projects, 29.4%,
33.3%, and 38.3%, respectively, had on-site facilities to perform
coronary angiography.
Data on patient demographics, clinical characteristics, in-
hospital management, and outcomes were collected by trainedcoordinators using standardized case report forms. The case
report forms were scanned or completed in a Web-based
manner and saved in an electronic central database for each
registry. Data checks were performed centrally with incomplete
or potentially incorrect data returned to the original sites for
revision and correction. Where required, the institutional
review board approved the study and participating patients
provided informed consent.
To avoid any potentially duplicate patients between Canadian
ACS Registries and GRACE/expanded-GRACE, the GRACE/
expanded-GRACE data used in this study included only the
period from January 2004 to December 2007. Therefore, this
study included 3,228, 1,956, and 7,299 NSTE-ACS patients,
respectively, in Canadian ACS I, ACS II, and GRACE/expanded-
GRACE, totaling 12,483 patients.Patient stratification
We categorized our study cohort (n = 12,483) on the basis of
prior coronary revascularization status into 4 mutually exclusive
groups: (1) no prior PCI or CABG, (2) prior PCI only, (3) prior
CABG only, and (4) both prior PCI and prior CABG. We
calculated the GRACE risk score, which is a previously validated
predictor of in-hospital mortality (c-statistic = 0.83) for each
patient.8,11,12 Briefly, the GRACE risk score is composed of age,
heart rate, systolic blood pressure, Killip class, cardiac arrest,
ST-segment deviation, serum creatinine level, and cardiac
biomarker status on presentation. The GRACE risk score
categories are low (≤108), intermediate (109-140), and high
(141-372), and the estimated risks of in-hospital death are b1%,
1% to 3%, and N3%, respectively.13 We could not determine the
GRACE risk score in 9.7% of the study population due to
incomplete data.Statistical analysis
Continuous variables are reported as medians with 25th and
75th percentiles, whereas frequencies and percentages are used
for categorical variables. Comparisons of continuous and
categorical variables between the different groups were made
by Kruskal-Wallis test and χ2 test, respectively. We performed
multivariable logistic regression to determine the adjusted odds
ratios and 95% CI for the in-hospital use of cardiac catheteriza-
tion in relation to prior coronary revascularization. To determine
their independent association, we adjusted for variables (ie,
female sex, registry, GRACE risk score, presence of on-site
cardiac catheterization facilities, coronary revascularization
status, prior stroke, congestive heart failure, and MI) previously
shown to be associated with in-hospital use of cardiac
catheterization14-19 and used generalized estimating equations
to account for the clustering of patients within hospitals.
Variables not associated with cardiac catheterization (P N .05)
were removed by backward elimination. To determine whether
prior revascularization by both PCI and CABG would be
associated with different treatment strategies, we tested for
their interaction in the multivariable model. Model calibration
and discrimination were evaluated by Hosmer-Lemeshow
goodness-of-fit test and c-statistic, respectively. A sensitivity
analysis was performed by excluding patients who died within
the first 48 hours of admission, as they might not have a chance
to undergo cardiac catheterization. Statistical analyses were
Table I. Baseline characteristics of study population stratified into 4 groups
Characteristic Overall
No prior
PCI/CABG
Prior
PCI only
Prior
CABG only
Prior PCI
and CABG
P (4-group
comparison
No. of patients (%) n = 12483 n = 8884 (71.2%) n = 1773 (14.2%) n = 1193 (9.6%) n = 633 (5.1%)
Age, y⁎ 68 (57-77) 67 (56-77) 66 (57-75) 72 (63-78) 70 (62-77)
Female sex 34.4% 37.1% 32.1% 23.5% 24.1% b.001
Current smoker 22.4% 24.4% 20% 15.3% 14.4% b.001
Dyslipidemia 54.5% 45.4% 76.2% 75.2% 82.8% b.001
Hypertension 60.6% 57.3% 67.8% 68.5% 73.3% b.001
Diabetes mellitus 28.3% 25.4% 33.1% 37.4% 38.7% b.001
Previous angina 53.3% 39.8% 84.7% 86.1% 91.5% b.001
Previous MI 35.7% 23.0% 65.1% 67.3% 73.0% b.001
Previous HF 11.1% 9.2% 11.9% 19.4% 19.6% b.001
Previous TIA or stroke 9.6% 8.8% 10.2% 13.5% 12.7% b.001
Heart rate, beat/min⁎ 76 (65-90) 78 (66-92) 71 (62-86) 74 (64-90) 72 (62-86) b.001
Systolic blood pressure, mm Hg⁎ 146 (128-165) 147 (130-167) 142 (124-160) 143 (124-163) 145 (127-162) b.001
Diastolic blood pressure, mm Hg⁎ 80 (70-91) 81 (70-93) 78 (68-89) 77 (66-87) 76 (68-87) b.001
Killip class .004
I 84.0% 84.2% 85.6% 80.2% 82.9%
II 11.3% 11.0% 10.7% 13.9% 12.5%
III/IV 4.7% 4.8% 3.7% 5.9% 4.6%
Cardiac arrest 0.7% 0.8% 0.3% 0.7% 0.2% .041
ST depression 27.5% 28.5% 21.3% 30.4% 26.4% b.001
T-wave inversion 20.3% 20.5% 17.1% 22.8% 20.7% .001
Abnormal cardiac biomarker 44.1% 49.3% 29.2% 34.3% 30.6% b.001
Serum creatinine, μmol/L⁎ 89 (75-109) 88 (74-107) 89 (75-108) 97 (80-121) 97 (78-120) b.001
GRACE risk score⁎ 119 (96-147) 119 (96-148) 113 (93-137) 129 (106-156) 122 (101-148) b.001
Data are given as percentage of each group unless indicated otherwise. GRACE risk score could not be determined in 9.7% of patients due to missing data. HF, Heart failure
TIA, transient ischemic attack.
⁎Data are presented as median (25th-75th percentile).
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2-sided P value of b.05 was considered statistically significant.
The Canadian ACS I and II Registries were sponsored by the
Canadian Heart Research Center (a federally incorporated not-
for-profit academic research organization), Merck, Kirkland,
Quebec (formerly Key Pharmaceuticals), Pfizer Canada Inc,
Kirkland, Quebec, Sanofi-Aventis Canada Inc, Laval, Quebec,
Bristol-Myers Squibb Canada, Montreal, Quebec. GRACE/
expanded-GRACE was sponsored by Sanofi-Aventis and Bristol-
Myers Squibb. The authors are solely responsible for the design
and conduct of this study, all study analyses, and the drafting and
editing of the paper and its final contents.
Results
Study population characteristics
Baseline demographic and clinical characteristics of
12,483 patients with NSTE-ACS, divided into 4 groups
according to prior coronary revascularization status are
shown in Table I. Of the 12,483 patients, 8,884 (71.2%) of
patients had no prior revascularization, 1,773 (14.2%) had
PCI only, 1,193 (9.5%) had CABG only, and 633 (5%) had
both PCI and CABG. Overall, the median (25th-75th
percentile) GRACE risk score was 119 (96-147).
Compared to the no prior PCI/CABG group, patients
in the PCI only, CABG only, and PCI and CABG groups
were more likely to be men, with higher preva-
lence rates of hypertension, diabetes, dyslipidemia,)
;previous angina, heart failure, and MI all P b .001 for
4-group comparisons).
Medication use within the first 24 hours of admission
Table II summarizes the use of antiplatelet and
antithrombin medications within the first 24 hours of
admission in patients stratified by coronary revascular-
ization status. Compared to the other groups, patients
with previous CABG were less likely to receive
antiplatelet and antithrombin therapies, except unfrac-
tionated heparin.
In-hospital outcomes
Table III compares the unadjusted rates of in-hospital
mortality and the composite of death/myocardial rein-
farction among 4 groups. The rates were highest in the
group without prior revascularization (P b .001).
In-hospital procedures
Table III shows the in-hospital use of cardiac proce-
dures in the 4 groups. The rates of cardiac catheterization
and PCI were lowest among patients with history of
CABG (45.2% and 18.0%, respectively) and highest in
those who had prior PCI only (57.9% and 30.4%,
respectively). The time to cardiac catheterization was
also longer for patients with prior CABG. After adjusting
Table II. Medication use in the first 24 hours of admission according to prior revascularization status
Medication use within the
first 24 h of admission
Overall
(n = 12483)
No prior
PCI/CABG
(n = 8884)
Prior PCI only
(n = 1773)
Prior CABG only
(n = 1193)
Prior PCI
and CABG
(n = 633)
P (4-group
comparison
Aspirin 91.8% 92.0% 92.4% 89.5% 91.5% .02
Ticlopidine/clopidogrel 49.3% 47.2% 60.0% 44.0% 58.3% b.001
Heparin (any) 88.1% 88.7% 86.5% 86.2% 87.5% .08
UFH 33.8% 33.9% 32.1% 35.8% 33.1% .23
LMWH 56.0% 56.4% 56.5% 52.2% 56.1% .05
Glycoprotein IIb/IIIa inhibitor 6.9% 7.2% 6.4% 5.2% 7.0% .08
UFH, Unfractionated heparin; LMWH, low-molecular-weight heparin.
Table III. In-hospital procedures and outcomes by prior coronary revascularization status
Procedure/outcome
Overall
(n = 12483)
No prior
PCI/CABG
(n = 8884 )
Prior PCI only
(n = 1773)
Prior CABG only
(n = 1193)
Prior PCI
and CABG
(n = 633)
P (4-group
comparison)
Cardiac catheterization 54.3% 55.0% 57.9% 45.2% 51.6% b.001
Time to cardiac catheterization (d)⁎ 3 (2-6) 3 (2-5) 3 (2-5) 4 (2-7) 4 (2-6) b.001
PCI 26.2% 26.3% 30.4% 18.0% 28.9% b.001
CABG 4.9% 5.5% 4.6% 2.1% 2.0% b.001
Any revascularization (PCI or CABG) 30.6% 31.3% 34.7% 19.9% 30.3% b.001
Death 1.9% 2.3% 0.7% 1.7% 0.9% b.001
In-hospital death/myocardial (re-)infarction 5.7% 6.4% 3.9% 3.9% 4.8% b.001
Data are presented as percentage unless indicated otherwise.
⁎Median (25th-75th percentile).
Table IV. Independent predictors of cardiac catheterization
during index hospitalization
Independent predictor
Adjusted odds
ratio (95% CI) P
Registry
ACS I Reference
ACS II 2.74 (1.71-4.38) b.001
GRACE/expanded-GRACE 2.54 (1.59-4.06) b.001
GRACE risk score
Low Reference
Intermediate 0.83 (0.72-0.95) .009
High 0.46 (0.37-0.57) b.001
On-site cardiac catheterization facilities 3.96 (2.65-5.91) b.001
Prior HF 0.51 (0.44-0.60) b.001
Prior MI 0.68 (0.58-0.79) b.001
Prior stroke 0.60 (0.50-0.72) b.001
Female sex 0.73 (0.65-0.82) b.001
Coronary revascularization status
No previous PCI/CABG Reference
Previous PCI⁎ 1.18 (1.04-1.34) .008
Previous CABG⁎ 0.77 (0.68-0.87) b.001
⁎ P for interaction between previous PCI and previous CABG = 0.93.
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predictors of in-hospital cardiac catheterization were
high and intermediate GRACE risk scores, previous
CABG, prior heart failure, MI, stroke, and female sex)(Table IV). Conversely, previous PCI was independently
associated with cardiac catheterization during index
hospitalization. There was no significant interaction (P
= .93) between previous PCI and CABG. The model c-
statistic was 0.72, and Hosmer-Lemeshow goodness-of-fit
test P value was .71, indicating adequate discrimination
and fit, respectively. Sensitivity analysis excluding
patients who died within 48 hours of admission (n =
56) provided similar results.
Discussion
In this large observational study, we found that patients
with history of PCI presenting with NSTE-ACS were more
likely to be managed invasively, which is consistent with
the current guideline recommendations.4 Conversely,
despite guideline recommendations, patients with previ-
ous CABG who were older, presented with worse Killip
class and higher GRACE risk score, less frequently
underwent cardiac catheterization and revascularization.
Furthermore, early use of evidence-based medications
was lower in the group with prior CABG only. These
findings suggest that physicians may underuse evidence-
based medical and invasive therapies for patients with
previous CABG.
With the increased availability and use of invasive
cardiac procedures in the past decade, a history of
coronary revascularization among ACS patients is
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on selected clinical trial populations have demonstrated
worse clinical outcomes of patients with previous CABG
compared to those without history of CABG.20-23
However, there are limited data on the management
patterns in relation to previous coronary revasculariza-
tion status in the “real world.”
Several landmark studies1-3 have shown the benefits of
an early invasive strategy in high-risk patients with NSTE-
ACS, as reflected in the current guidelines.4 However,
FRISC II1 and RITA-33 excluded patients with prior CABG
and in the TACTIC-TIMI 18 study,2 patients with CABG
within the prior 6 months were excluded. Furthermore,
the more recent ICTUS trial24 included only a small
number of CABG patients (8.7%), and it failed to prove
superiority of an early invasive strategy to a selective
invasive strategy in patients with NSTE-ACS and elevated
troponin. Thus, there appears to be a lack of conclusive
evidence to guide the use of invasive strategy in the
management of NSTE-ACS patients who have prior CABG.
Several observational studies have examined the
relationship between invasive treatment and outcome
in patients with previous CABG. Gurfinkel et al25
evaluated the in-hospital and 6-month outcome of 3,853
ACS patients with prior CABG. Of these patients, 497
patients underwent invasive treatment within 48 hours of
admission, whereas 3,356 were managed noninvasively.
There was no statistically significant difference in hospital
outcomes (primary composite of death, nonfatal MI, and
recurrent ischemia) between the invasive and noninva-
sive treatment groups. However, 6-month mortality rate
was significantly lower in the invasive group compared to
the noninvasive group. Patients treated invasively expe-
rienced higher readmission rates and repeat cardiac
procedures but lower incidence of cardiac events after
6 months. Similarly, in the GUSTO IV study, coronary
revascularization within 30 days of admission was
associated with reduced 1-year mortality in NSTE-ACS
patients.26 However, of the 2,265 patients who under-
went revascularization within 30 days, only 9% had a
history of CABG. In a large Swedish registry study of
10,837 patients b80 years old who had previous CABG,27
revascularization within 14 days of hospital admission
for NSTE-ACS was associated with a marked reduction in
1-year mortality (5.4% vs 13.1%).
There is also limited evidence to support the routine
use of an early invasive strategy specifically in the
management of ACS patients with prior PCI. The pre-
valence of previous PCI in the ICTUS trial was 11.7%, and
in TACTICS-TIMI 18, PCI within 6 months was an
exclusion criterion. In a post hoc analysis of 3 clinical
trials (GUSTO IIb, PURSUIT, PARAGON-B), 3,012 patients
with prior PCI and 21,154 patients without prior PCI who
presented with NSTE-ACS were assessed for 30-day and
180-day outcomes. Significantly lower mortality rates
at 30 days and 180 days were observed in the prior PCIgroup.28 In the present study of less selected ACS
patients, the group with prior PCI had lower unadjusted
rates of in-hospital mortality and death/(re-)MI. In
contrast, Sanchis et al29 found that prior PCI is an adverse
prognosticator among NSTE-ACS patients with normal
troponin levels.
Our study shows that history of CABG was associated
with lower use of aspirin, thienopyridine, and GP IIb/IIIa
inhibitors compared with the other groups. Aspirin and
clopidogrel are the cornerstones for both invasive and
conservative management of ACS patients.4 The Clopido-
grel in Unstable angina to prevent Recurrent Event
(CURE) trial,30 which demonstrated the efficacy of
clopidogrel, included patients with prior revasculariza-
tion (17.9%). Those patients in fact derived an even
greater benefit (hazard ratio 0.56 vs 0.88, P for interaction
= .002), although this subgroup analysis combined
patients with prior CABG and those with prior PCI. In
the present study, clopidogrel was significantly under-
used in the group with previous CABG only. Similarly,
GP IIb/IIIa inhibitors reduce the rates of death and MI
in ACS patients undergoing PCI.31,32 Several subgroup
analyses have specifically assessed the benefit of GP IIb/
IIIa inhibitors in patients with prior CABG.22,33 Labinaz
et al22 assessed the 30-day and 180-day outcomes of 1,134
patients with prior CABG enrolled in the Platelet
Glycoprotein IIb/IIIa in Unstable Angina: Receptor
Suppression with Integrilin Therapy (PURSUIT) Trial.
Although patients with prior CABG had higher mortality
rate at 30 days and at 180 days than those without CABG,
the effect of eptifibatide appears to be similar on primary
end point of death or MI in both groups. In another
subgroup analysis, Servoss et al33 assessed the effect of
tirofiban on the outcomes of patients with previous
CABG presenting with ACS in the Platelet Receptor
Inhibition in Ischemic Syndrome Management in Patients
Limited by Unstable Signs and Symptoms (PRISM-PLUS)
trial. Among patients with prior CABG, compared to
heparin alone, tirofiban, and heparin reduced the
incidence of death, MI, or refractory ischemia at 7 and
30 days. Together, these data suggest that patients with
previous CABG may derive similar benefits from these
evidence-based therapies. Thus, our findings imply a
disparity between evidence and practice in the medical
treatment of ACS patients with prior CABG.
Although the present study identifies important gaps in
the management of ACS patients with prior revasculari-
zation, the underlying reasons remain to be determined.
Of note, the patients with prior CABGwere more likely to
be older, with higher rates of diabetes mellitus, heart
failure, cerebrovascular disease, and renal dysfunction.
These comorbidities may deter physicians from recom-
mending more intensive treatment,18,19 although the
independent association between prior CABG and lower
use of cardiac catheterization was maintained even after
controlling for these factors. Nevertheless, these higher
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benefit, so that the risk-benefit ratio may be favorable, at
least among carefully selected patients. It is also possible
that the underrepresentation or exclusion of patients
with previous revascularization in major clinical trials
may have contributed to the lower use of these therapies
by physicians.Study limitations
Although recruitment of consecutive patients was
encouraged in all 3 registries, this could not be verified.
Second, we did not collect data on coronary anatomy and
the time of prior revascularization. For example, ACS
patients with prior CABG and recent cardiac catheteriza-
tion showing coronary anatomy not amenable to repeat
revascularization would be treated conservatively. Third,
we did not consider the patient preference for treatment.
It is possible that due to higher procedural risk for
revascularization (especially surgical), patients with prior
CABG might prefer conservative medical treatment.
Fourth, despite applying statistical methods that attempt
to adjust for potential confounders, we may not have
accounted for all the measured and unmeasured char-
acteristics that may contribute to the physicians' deci-
sions to not proceed with an invasive strategy and/or
administer certain medical therapies. Fifth, the mortality
rate was low because early deaths might have been
excluded (due to the need for informed consent). Finally,
we did not evaluate long-term outcomes in relation to
revascularization, although this has been the focus of
previous studies.Conclusions
Despite current guidelines recommendations and a
higher risk profile, ACS patients with prior CABG were
less likely to receive evidence-based medical and invasive
therapies. Conversely, patients with previous PCI are
more likely to receive intensive medical and invasive
therapies, compared to the CABG group. More definitive
data from randomized controlled trials may help to guide
the optimal treatment of these ACS patients. Further-
more, quality improvement measures to ensure proper
implementation of up-to-date management guidelines in
the “real world” are warranted.Acknowledgements
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